Twist Bioscience (TWST) Stock Price, News & Analysis

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TWST shares.
View TWST analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12 month price objectives for Twist Bioscience's shares. Their TWST share price targets range from $27.00 to $45.00. On average, they predict the company's stock price to reach $36.40 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts price targets for TWST or view top-rated stocks among Wall Street analysts.

Twist Bioscience's stock was trading at $36.86 at the beginning of the year. Since then, TWST shares have decreased by 22.4% and is now trading at $28.61.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our TWST earnings forecast.

Twist Bioscience Co. (NASDAQ:TWST) released its quarterly earnings results on Friday, February, 2nd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.03. The company had revenue of $71.50 million for the quarter, compared to analysts' expectations of $67.59 million. Twist Bioscience had a negative net margin of 78.44% and a negative trailing twelve-month return on equity of 32.16%. The company's revenue was up 31.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.74) EPS.

ETFs with the largest weight of Twist Bioscience (NASDAQ:TWST) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Subversive Mental Health ETF (SANE), iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Innovation ETF (ARKK) and Putnam BioRevolution ETF (SYNB).

Twist Bioscience updated its second quarter 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $70.0 million-$71.0 million, compared to the consensus revenue estimate of $70.1 million.

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

Twist Bioscience (TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional investors include Green Alpha Advisors LLC (0.03%). Insiders that own company stock include Adam Laponis, Dennis Cho, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess, Robert F Werner and William Banyai.
View institutional ownership trends.

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.